19. The combination of any one of claims 1 to 18, further comprising an effective amount of an additional therapeutic agent.

20. The combination of claim 19, wherein said additional therapeutic agent is an anticancer agent.

21. The combination of claim 20, wherein said anticancer agent is an antimetabolite, an inhibitor of topoisomerase I and II, an alkylating agent, a microtubule inhibitor, an antiandrogen agent, a GNRh modulator or mixtures thereof.

22. The combination of claim 21, wherein said additional therapeutic agent is a chemotherapeutic agent selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, imatanib, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, cytarabine, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristine, vinblastine, nocodazole, teniposide etoposide, gemcitabine, epothilone, vinorelbine, camptothecin, daunorubicin, actinomycin D, mitoxantrone, acridine, doxorubicin, epirubicin, or idarubicin.

23. The combination of any one of claims 1 to 22, wherein said immunotherapeutic is of an amount that is capable of:

(1) inducing IFN-α in a enriched human blood DCs;

(2) inducing TNF-α in a enriched human blood DCs; and/or

(3) inducing IL-12-α in a enriched human blood DCs.

24. Use of the combination of any one of claims 1-23 in the manufacture of a medicament for the treatment of tumor.

25. Use of the combination of any one of claims 1-23 in the manufacture of a medicament for the treatment of abnormal cell proliferation.

26. The use of claim 25, wherein said abnormal cell proliferation comprises a pre-cancerous lesion.

27. The use of claim 25, wherein said abnormal proliferation is of cancer cells.

28. The use of claim 27, wherein said cancer is selected from the group consisting of: breast cancer, colorectal cancer, diffuse large B-cell lymphoma, endometrial cancer, follicular lymphoma, gastric cancer, glioblastoma, head and neck cancer, hepatocellular cancer, lung cancer, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, and renal cell carcinoma.

29. The use of any one of claims 24 to 28, wherein the medicament comprises an oral formulation comprising said immunotherapeutic in a dose of between about 0.0005 mg/kg, 0.0006 mg/mg/kg, 0.0007 mg/kg, 0.0008 mg/kg, 0.0009 mg/kg, 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, or 0.01 mg/kg, to about 0.02 mg/kg, all inclusive, twice per week.

30. The use of any one of claims 24 to 28, wherein the medicament comprises an oral formulation comprising said immunotherapeutic in a dose of less than or about 0.0005mg/kg, 0.0006 mg/kg, 0.0007 mg/kg, 0.0008 mg/kg, 0.0009 mg/kg, 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, or 0.01 mg/kg, twice per week.

31. The use of any one of claims 24 to 28, wherein the medicament comprises an intravenous formulation comprising said immunotherapeutic in a dose of between about 0.0005 mg/kg, 0.0006 mg/kg, 0.0007 mg/kg, 0.0008 mg/kg, 0.0009 mg/kg, 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg, or 0.006 mg/kg to about 0.015 mg/kg, all inclusive, weekly.

32. The use of any one of claims 24 to 28, wherein the medicament comprises an intravenous formulation comprising said immunotherapeutic in a dose of less than or about 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg, or 0.006 mg/kg, to about 0.01 mg/kg, weekly.

33. The use of any one of claims 24 to 32, wherein said immunotherapeutic has a local concentration that is between about 0.005 μg/ml to about 12 μg/ml.

34. The use of any one of claims 24 to 32, wherein said immunotherapeutic has a local concentration that is between about 0.05 μg/ml, 0.1 μg/ml, 0.15 μg/ml, 0.2 μg/ml, 0.3 μg/ml, or 0.4 μg/ml, to about 0.5 μg/ml.

35. A kit, comprising the combination of any one of claims 1 to 23.